Global Behavioral and Mental Health Software Market

Mental health apps refer to mobile and PC-based applications used by people to manage their mental health. These apps help people to manage their medications and help in reducing stress and monitoring symptoms of disorders. The user can get therapies virtually for conditions such as PTSD, psychotic disorders, anxiety disorders, and others. The main platforms used in mental health apps include IOS, Android, and others. The iOS mental health apps refer to mental health and wellness used in iOS-enabled mobile phones or tablets. IOS is an operating system developed by Apple Inc., for mobile devices. These applications are used for depression and anxiety management, meditation management, stress management, wellness management, and others. The mental health apps market research report is one of a series of new reports from The Business Research Company that provides mental health apps market statistics, including mental health apps industry global market size, regional shares, competitors with a mental health apps market share, detailed mental health apps market segments, market trends and opportunities, and any further data you may need to thrive in the mental health apps industry. This mental health apps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global mental health apps market size grew from $5.49 billion in 2022 to $6.36 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mental health apps market size is expected to grow to $11.62 billion in 2027 at a CAGR of 16.3%. The increasing awareness about mental health and its significance is propelling the growth of the mental health apps market. Increasing openness about mental health by sports personalities and celebrities has reduced the stigma and increased awareness about mental health and its importance on one’s health across the globe. Additionally, individuals with mental health-related problems are investing in various recovery therapies such as medical consultations, mental health apps, self-help books, and others. For instance, according to the study published by National Alliance for Mental Illness, in 2020, more than 21% of USA adults experienced mental illness, and more than 26.3 million adults received virtual mental health services. Therefore, the increasing awareness of mental health and its awareness drive the mental health app market. Technological advancement is a key trend gaining popularity in the mental health apps market. Major companies operating in the mental health apps market are focused on providing technologically-advanced solutions to meet end-customer demands and strengthen their market position. These companies are implementing next-generation technologies into their services, such as CRM, video API, text API, and end-to-end patient engagement through AI and ML and others. For instance, In January 2021, Moody, a health care company, launched an intelligent mental health care app that can identify and alert the user about psychological changes in their behaviour ahead of time and recommend corrective actions daily. It allows the user to create daily journal entries with memories such as pictures, attachments, and others. In January 2021, Headspace Health, a UK-based provider of digital mental health and wellbeing solutions, acquired Sayana for an undisclosed amount. Through this acquisition, Headspace is focused on integrating AI capabilities into its systems, providing better mental health services to customers and personalized user experiences. Sayana is an India-based provider of AI-powered mental health and wellness solutions. Major players in the mental health apps market are Mindscape, Calm, MoodMission, Headspace, Flow Neurosciences, Youper, Happify, Sanvello, NOCD, Talkspace, Addicaid, Silvercloud Health, Moodfit, BetterHelp, and eMoods. North America was the largest region in the mental health apps market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mental health apps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the mental health apps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The mental health apps market includes revenues earned by entities by providing services such as self-awareness by controlling their mood, maintaining good habits and breaking bad ones, and cultivating positive thinking. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mental health apps market is segmented - 1) By Platform Type: iOS, Android, Other Platform Types 2) By Application Type: Depression and Anxiety management, Meditation Management, Stress Managemet, Wellness Management, Other Application Types

Psychiatrists provide the diagnosis, treatment, and prevention of mental, emotional, and behavioral disorders. Psychiatrists are licensed practitioners with a degree of M.D. (Doctor of Medicine) or D.O. (Doctor of Osteopathic Medicine) who provide palliative care and treat psychosomatic disorders, mental disorders, and others. They operate private or group practices in their own offices (e.g., centers, clinics) or in the facilities of others, such as hospitals or health maintenance organizations (HMO) medical centers. The main mental disorder types of psychiatrists are alcohol abuse mental and behavioral disorders, psychoactive substances that use mental and behavioral disorders, schizophrenia, schizotypal and delusional disorders, mood (anxiety and depression) disorders, and other mental and behavioral disorders. The patient types are inpatient and outpatient. The psychology types are social, abnormal, biological, and others. The psychiatrists market research report is one of a series of new reports from The Business Research Company that provides psychiatrists market statistics, including psychiatrists industry global market size, regional shares, competitors with a psychiatrists market share, detailed psychiatrists market segments, market trends and opportunities, and any further data you may need to thrive in the psychiatrists industry. This psychiatrists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global psychiatrists market size will grow from $147.28 billion in 2022 to $164.01 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psychiatrists market size is expected to grow from $231.47 billion in 2027 at a CAGR of 9.0%. The rising government support for mental health reforms is expected to propel the growth of the psychiatrist market going forward. Support for mental health resources led to a demand for mental care and drove the psychiatrist market. For instance, according to Business Insider, a US-based financial and business news website, Chile announced an over 300% increase in the mental health budget in 2021 and Canada announced a $1 billion fund allocation for mental health in its Budget 2021. Therefore, rising government support for mental health reforms is driving the growth of the psychiatrist market. The new studies associated with psychiatric genetics are discovering complex disorders related to mental health are a key trend gaining popularity in the psychiatrists market. Psychiatric genetics studies the role of genetics in the causes of mental health and provides knowledge to improve treatment methods. For instance, scientists discovered causes related to anorexia, an eating disorder. The researchers found that the problems related to this disorder were driven by metabolism. The researchers compared nearly 17,000 anorexia symptomatic people’s DNA with more than 55,000 healthy controls. The study revealed eight genes that linked anorexia to anxiety, depression, and obsessive-compulsive disorder, all of which were expected. Ultimately, these genetic discoveries will provide clues to the major mental disorders. The major players covered in the psychiatrists market are UK NHS, Universal Health Services, Massachusetts General Hospital, New York-Presbyterian University Hospital, Mayo Clinic, Johns Hopkins Hospital, McLean Hospital, Mental Health and Neurosciences, Vidyasagar Institute of Mental Health and Neurosciences, Central Institute of Psychiatry, Institute of Behaviour and Allied Sciences North America was the largest region in the Psychiatrists market in 2022. The regions covered in the psychiatrists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psychiatrist's market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The psychiatrists market includes revenues earned by entities by providing psychiatrist services such as mental disorder treatments, anxiety disorders treatments, depression treatments, disruptive behavior and dissocial disorders treatments, and neurodevelopmental disorders treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global psychiatrists market is segmented - 1) By Mental Disorder Type: Alcohol Abuse Mental And Behavioral Disorders, Psychoactive Substance Use Mental And Behavioral Disorders,Schizophrenia, Schizotypal And Delusional Disorders, Mood (Anxiety And Depression) Disorders, and Other Mental And Behavioral Disorders 2) By Patient Type: Inpatient, and Outpatient 3) By Psycology Type: Social, Abnormal, Biological, Other Psycology Types

Telepsychiatry refers to the delivery and assistance of clinical psychiatric care, including medical care, providing patient education, health information services, and self-care through telecommunications and digital communication technologies. The main types of telepsychiatry are routine telepsychiatry, forensic telepsychiatry, crisis telepsychiatry, and in-home telepsychiatry. Routine telepsychiatry involves a consistent provider or small group of providers serving a regular caseload of consumers in previously scheduled blocks of time. The age groups are adult, paediatric and adolescent, and geriatric. The various end-users involved are community mental health centers, specialty care settings, skilled nursing facilities, home care, and other end-users. The telepsychiatry market research report is one of a series of new reports from The Business Research Company that provides telepsychiatry market statistics, including telepsychiatry industry global market size, regional shares, competitors with a telepsychiatry market share, detailed telepsychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the telepsychiatry industry. This telepsychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global telepsychiatry market size grew from $7.7 billion in 2022 to $9.78 billion in 2023 at a compound annual growth rate (CAGR) of 27.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The telepsychiatry market size is expected to grow to $22.52 billion in 2027 at a CAGR of 23.2%. The increase in demand for mental health treatment is expected to propel the growth of the telepsychiatry market going forward. Mental health refers to the cognitive, behavioral, and emotional well-being of a person. Psychologists are reporting a large increase in demand for the treatment of anxiety and depression. For instance, in 2021, according to the American Psychological Association, a US-based professional organisation that represents psychologists, nearly 84% of psychologists who treat anxiety disorders said they have seen increased demand for anxiety treatment since the pandemic when compared with the last decade when it was 74%. Also, 72% of psychologists said that there was an increase in depression prevalence compared with 60% in 2020. Therefore, the increase in demand for mental health treatment is driving the growth of the telepsychiatry market. Technological advancements are key trends gaining popularity in the telepsychiatry market. Major companies operating in the telepsychiatry market are focused on developing new technological solutions to strengthen their position. For instance, in December 2021, Zoom Video Communications Inc., a US-based communications technology company, along with Cerner Corp.'s electronic health record platform and a US-based company that provides telepsychiatry, launched an integration option for facilitating easier access to telehealth within Cerner's EHR. This includes the in-chart notifications when the patient has entered the appointment waiting room and the ability to send an invite link to additional participants, like family members, interpreters, and other care providers, and is accessible to join the session. In December 2021, Quartet Health, a US-based tech-enabled mental health care company, acquired InnovaTel Telepsychiatry for an undisclosed amount. Through this acquisition, Quartet will develop market-leading care delivery capabilities to complement its existing ecosystem of high-performing clinicians who practise in-network on behalf of health insurance plans. InnovaTel Telepsychiatry is a US-based telepsychiatry service provider of psychiatrists, nurse practitioners, and licenced clinical social workers. Major players in the telepsychiatry market are AllScripts Healthcare Solutions Inc., Cerner Corporation, Sodexo S.A., LogistiCare Solutions LLC, The Allure Group, Aramark Corporation, Alere Inc., Flatworld Solution, Integrated Medical Transport, ABM Industries Inc., Advanced Telemed Services, American Telepsychiatrists, Encounter Telehealth LLC, InnovaTel Telepsychiatry, SOC Telemed, and Telemynd. North America was the largest region in the telepsychiatry market in 2022. The regions covered in the telepsychiatry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telepsychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telepsychiatry market includes revenues earned by entities by providing psychiatric evaluation and diagnosis services, individual therapy services, group therapy services, and family therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global telepsychiatry market is segmented - 1) By Type: Routine Telepsychiatry, Forensic Telepsychiatry, Crisis Telepsychiatry, In-Home Telepsychiatry 2) By Age Group: Adult, Pediatric and Adolescent, Geriatric 3) By End-Use: Community Mental Health Centers, Specialty Care Settings, Skilled Nursing Facilities, Homecare, Other End-Users 

Residential substance abuse and mental health facilities are treatment centres where patients can stay and undergo treatment. These centres are used to provide treatment with 24/7 monitoring of the patient. The main types of residential substance abuse and mental health facilities are residential mental health and intellectual disability facilities, and substance abuse centres. Substance abuse centres provide substance abuse treatment and recovery services for individuals and families. The different expenditure types include public and private are used by male and female. The residential substance abuse and mental health facilities market research report is one of a series of new reports from The Business Research Company that provides residential substance abuse and mental health facilities market statistics, including residential substance abuse and mental health facilities industry global market size, regional shares, competitors with a residential substance abuse and mental health facilities market share, detailed residential substance abuse and mental health facilities market segments, market trends and opportunities, and any further data you may need to thrive in the residential substance abuse and mental health facilities industry. This residential substance abuse and mental health facilities market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global residential substance abuse and mental health facilities market grew from $106.52 billion in 2022 to $115.53 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The residential substance abuse and mental health facilities market is expected to grow to $152.11 billion in 2027 at a CAGR of 7.1%. Autism and Attention Deficit and Hyperactivity Disorder (ADHD) cases are increasing in most parts of the world. ADHD is defined by impaired functioning in the areas of attention, hyperactivity, and impulsivity and autism is a neurodevelopmental disorder characterized by impaired social interaction, verbal and non-verbal communication, and restricted and repetitive behavior. According to Centres for Disease Control and Prevention (CDC), around one in every 54 children in the US has an autism spectrum disorder (ASD) in 2020. Increasing incidences of mental issues is expected to drive this market growth going forward. Mental health and substance abuse service costs are high in most countries. Pressure from regulatory bodies to contain costs and demonstrate value is widespread among mental health and substance abuse service providers. Prevailing weak economic conditions are a deterrent to substance abuse and mental health facilities funding. Also, the high cost of targeted therapies, medication, medical devices, and other advances continues to add to the substance abuse and mental health cost burden and acts as a restraint to the residential substance abuse and mental health facilities during the forecast period. Medical service providers are using technology-based interventions to aid in the treatment of substance abuse patients. Technology is used to deliver interventions via digital platforms with the intention to treat substance use disorders by providing emotional, decisional or behavioural support for physical and mental health problems. These technology-based interventions include internet technology-mediated therapy, web-based self-help interventions and virtual therapeutic software. Also, self-guided and web-based education interventions are enabling people to access information about specific symptoms, diagnosis of condition effect on patient health and treatments, provide communication between a therapist and patient through the internet. For instance, major hospitals offering technology-based interventions for substance abuse disorders include Mayo Clinic, Texas Medical Centre, Johns Hopkins, The London Clinic, American Hospital and Fortis Memorial Research Institute. Major companies in the residential substance abuse and mental health facilities market include Kaiser Permanente, universal health services, Ohio Department of Mental Health and Addiction Services, NHS England, Acadia Healthcare Company, CareTech Holdings PLC, and Pyramid Healthcare. North America was the largest region in the residential substance abuse and mental health facilities market in 2022. Western Europe was the second largest region in the residential substance abuse and mental health facilities market. The regions covered in the residential substance abuse and mental health facilities market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the residential substance abuse and mental health facilities market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The residential substance abuse and mental health facilities market includes revenues earned by entities by providing mental health services, substance prevention services, and substance rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global residential substance abuse and mental health facilities market is segmented - 1) By Type: Residential Mental Health & Intellectual Disability Facilities, Substance Abuse Centers 2) By End User Gender: Male, Female 3) By Type of Expenditure: Public, Private Subsegments Covered: Residential Intellectual And Developmental Disability Facilities, Residential Mental Health Facilities, Illicit Drugs Addiction Treatment, Alcohol Addiction Treatment, Tobacco Addiction Treatment

Psychedelic drug refers to a group of psychoactive drugs that alter perception, mood, and thought processes. All of the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. These include chemicals such as Lysergic acid diethylamid (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions. The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drug market statistics, including psychedelic drug industry global market size, regional shares, competitors with a psychedelic drug market share, detailed psychedelic drug market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global psychedelic drugs market size grew from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psychedelic drugs market size is expected to grow to $8.31 billion in 2027 at a CAGR of 14.5%. The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drug market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drug market. The introduction of "depression spray" is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal spray drugs for major depressive disorders to sustain their position in the market. For instance, in August 2021, Hikma Pharmaceuticals plc, a UK based pharmaceutical company, launched KLOXXADO. KLOXXADO is an 8 mg nasal spray containing naloxone HCl. This spray is used for the immediate care of patients, both adults and children, with known or suspected opioid overdoses, as shown by respiratory depression and/or central nervous system depression. In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine. Major players in the psychedelic drug market are Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc., Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc., AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Allergan Inc., Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG. North America was the largest region in the psychedelic drug market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psychedelic drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The psychedelic drug market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global psychedelic drugs market is segmented - 1) By Type: Lysergic Acid Diethylamid (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia 2) By Disease Indication: Depression, PTSD 3) By Origin: Natural, Synthetic 4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders 5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy

Antidepressants refer to a medication that aids in the treatment of depressive symptoms. Additionally, they can aid in the treatment of SAD, other anxiety disorders, and social anxiety disorder. Unpleasant side effects are possible with antidepressants. Initially, signs and symptoms including nausea, weight gain, or sleep issues can be prevalent. The main product types of antidepressants are selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), and monoamine oxidase inhibitor (MAOI). SSRIs (selective serotonin reuptake inhibitors) are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various drug class includes monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants that are used for the treatment of the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder. The antidepressants market research report is one of a series of new reports from The Business Research Company that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global antidepressants market grew from $16.44 billion in 2022 to $17.41 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antidepressants market is expected to grow from $25.52 billion in 2027 at a CAGR of 10.0%. The antidepressants market has also surged during the COVID-19 outbreak. The increasing number of cases and fatalities is affecting mental health by elevating anxiety worldwide. People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak. This has triggered the demand for antidepressant drugs. Globally, rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder, and other mental diseases. Antidepressant medications are used in conditions such as depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Globally, the percentage of people with depression varies from 2% to 6%, and the elderly are at greater risk of depression compared to other age groups. According to WHO, in 2020, about 264 million people of all ages worldwide suffered from depression. Therefore, rising cases of mental health disorders are expected to drive the growth of the antidepressant market. The side effects of antidepressant drugs are a key factor hampering the growth of the antidepressant market. For instance, the antidepressants Lexapro (escitalopram) and Celexa (citalopram), both are used to treat depression and Lexapro also helps for treating anxiety. Lexapro and Celexa can cause side effects common to others which include nausea, sleeplessness, sweating, dry mouth, and drowsiness. Celexa and Lexapro are both at risk for even more serious side effects including excessive bleeding, seizures, and vision issues. Therefore, the side effects of antidepressant drugs are expected to limit the growth of the antidepressant market. The treatment of resistant depression is a key trend in the antidepressant market. Ketamine is the new treatment that is used for anesthesia during surgery, stimulates the development of glutamate, and prompts the brain to form new neural connections. It makes the brain more adaptable and capable of developing new pathways and helps people to create more optimistic thoughts and behaviors. For instance, Food and Drug Administration (FDA) approved a new ketamine depression drug esketamine which is one-half of the ketamine compound. The drug must be administered as a nasal spray and patients must be taking another antidepressant at the same time. Also, the drugs can be prescribed to only those patients who have (unsuccessfully) tried two antidepressants before. In October 2021, ShineCo., Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, and other biotech products, announced that it has entered into a framework agreement to acquire a majority stake in Beijing Wonner Biotech Co., Ltd., for a deal amount of $30 million. Through this acquisition, Shineco aims to jointly develop SNG, a rapid-acting antidepressant natural innovative medicine. Beijing Winner is a biotechnology company based in China that specializes in the research and development of natural medicines and related products. Major players in the antidepressants market are Allergan PLC., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC., H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun Pharmaceuticals Pvt Ltd., Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd., Forest laboratories and Akeda Pharmaceutical. North America was the largest region in the antidepressants market in 2022. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the global antidepressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antidepressants market is segmented - 1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI) 2) By Drug Class: Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants 3) By Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder

 Bipolar disorder therapeutics refer to medication, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, to control symptoms. The bipolar disorder therapeutic is used in the treatment and management of bipolar disorders. The main types of drugs in bipolar disorder therapeutics are mood stabilizers, antipsychotic drugs, antidepressant drugs, and other drugs. Mood stabilizers refer to a class of medications used in the management and treatment of bipolar disorders. The different mechanisms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The bipolar disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bipolar disorder therapeutics market size grew from $6.51 billion in 2022 to $6.93 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bipolar disorder therapeutics market size is expected to grow to $8.36 billion in 2027 at a CAGR of 4.8%. The increase in the prevalence of bipolar disorder is expected to propel the growth of the bipolar disorder therapeutics market going forward. Bipolar disorder refers to a disabling illness that is associated with depressive mood swings and includes symptoms such as irregular sleep, low motivation, and loss of interest in daily activities. Population growth and aging are leading to an increase in the burden of bipolar disorder over time. As a result, an increase in the prevalence of bipolar disorder increases the demand for the bipolar disorder therapeutics market. For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to the patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness.  Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market. Strategic partnerships have emerged as a key trend gaining popularity in the bipolar disorder therapeutics market. Major companies operating in the bipolar disorder therapeutics sector are focused on partnerships to reinforce their position. For instance, in October 2021, Mindpax Inc., a Germany-based digital technology company operating in the bipolar disorder therapeutics market, partnered with Eversana Life Science Services LLC, a US-based life sciences company operating in the bipolar disorder therapeutics market. Through this partnership, both companies will develop remote clinical assessments and targeted digital therapy to improve patients' clinical conditions and provide personalized therapeutic interventions to bipolar patients. Furthermore, in November 2020, Biogen, a US-based biotechnology company, partnered with Sage Therapeutics, a US-based company that develops novel therapies including bipolar. Through this partnership, both businesses will work together to commercialize zuranolone (SAGE-217) for significant postpartum depression (PPD), depressive disorder (MDD), and other psychiatric diseases. In May 2020, AbbVie, a US-based biopharmaceutical company, acquired Allergan plc for a deal amount of $63 billion. AbbVie's revenue base is expected to broaden and diversify, complementing existing leadership positions in immunology (with Humira (adalimumab) and hematologic oncology (with Imbruvica (ibrutinib) and Venclexta (upadacitinib), and the recently launched Skyrizi (risankizumab) and Rinvoq (upadacitinib) (venetoclax). Allergan is an Ireland-based specialty pharmaceutical company that develops pharmaceuticals and biosimilar products, including those for bipolar disorder. Major players in the bipolar disorder therapeutics market are AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd., and H. Lundbeck A/S. North America was the largest region in the bipolar disorder therapeutics market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bipolar disorder therapeutics market is segmented - 1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs 2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Healthcare services are the medical services provided to the people who are in need by healthcare professionals, organizations and healthcare workers. These services are provided to patients, families and communities. The main types of healthcare services are medical and diagnostic laboratory services, dental services, home health care and residential nursing care services, residential substance abuse and mental health facilities, hospitals and outpatient care centres, physicians and other health practitioners, all other ambulatory health care services, and ambulance services. The hospitals and outpatient care centres are engaged in providing diagnostic and medical treatment to patients with a wide range of medical conditions. The different expenditure types include public and private which are used by male and female. The healthcare services market research report is one of a series of new reports from The Business Research Company that provides healthcare services market statistics, including healthcare services industry global market size, regional shares, competitors with a healthcare services market share, detailed healthcare services market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare services industry. This healthcare services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global healthcare services market grew from $7,499.75 billion in 2022 to $7,975.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The healthcare services market is expected to grow to $9,816.85 billion in 2027 at a CAGR of 5.3%. Survival rates and quality of life have improved tremendously over the past decade. Medical and technological advances have played an important role in their progress. High technology diagnostics and therapeutic equipment integrating doctors’ practice patterns have improved healthcare services delivery. According to a report by TrendWatch, medical advances are responsible for a 70% improvement in survival rates for heart attack patients and a two-thirds reduction in mortality rates for those suffering from cancer. These factors contribute to the potential growth of the market. Many federal and state governments are either offering subsidized or free healthcare services to their citizens. Since most of the governments are offering quality healthcare services for free or subsidized rates, patients tend to opt for government healthcare services thereby, limiting the scope for private healthcare service providers. For example, the NHS (National Health Service) of the UK offers free healthcare services to all legal residents and visitors. Going forward, federal and state provisions are expected to be a major restraint on the healthcare services market. The shared medical appointments (SMA) model is being increasingly adopted globally to optimize resources and reduce costs. This is a model generally defined as multiple patients being seen as a group by a multi-disciplinary medical care team for follow-up or routine care. It is being adopted by hospitals to create awareness and counsel individual patients dealing with similar medical conditions. The SMA supplements the traditional physician-patient appointment. SMAs provide individual evaluation and disease management for each patient at the same time that they provide counseling to the patient within a group setting. SMAs are currently used to address diabetes, asthma, ulcerative colitis, MS, cancer, HIV, menopause, insomnia and stress. Major companies in the market include UnitedHealth Group Incorporated, Kaiser Permanente, HCA Healthcare, Fresenius Medical Care AG & Co. KGaA, Tenet Healthcare, Mayo Clinic, Community Health Systems, Laboratory Corporation of America, Cleveland Clinic and Davita Inc. North America was the largest region in the healthcare services market in 2022. Western Europe was the second largest region in the healthcare services market. The regions covered in the healthcare services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the healthcare services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The healthcare services market includes revenues earned by entities by providing human healthcare services such as medical and diagnostic laboratory services, dental services, nursing care, residential substance abuse and mental health facilities and other healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global healthcare services market is segmented - 1) By Type: Medical And Diagnostic Laboratory Services, Dental Services, Home Health Care And Residential Nursing Care Services, Residential Substance Abuse And Mental Health Facilities, Hospitals And Outpatient Care Centers, Physicians And Other Health Practitioners, All Other Ambulatory Health Care Services, Ambulance Services 2) By End User Gender: Male, Female 3) By Type of Expenditure: Public, Private Subsegments Covered: Medical Laboratory Services, Diagnostic Imaging Centers, General Dentistry, Oral Surgery, Orthodontics And Prosthodontics, Other Dental Services, Home Health Care Providers, Nursing Care Facilities, Orphanages & Group Homes, Retirement Communities, Residential Mental Health & Intellectual Disability Facilities, Substance Abuse Centers, Hospitals, Outpatient Care Centers, Specialist Doctors, Primary Care Doctors, Physical Therapists, Optometrists, Chiropractors, Podiatrists, Ground Ambulance Services, Air Ambulance Services, Water Ambulance Services